Blockbuster drugs worth hundreds of billions face generic competition as patents expire through 2032. Indian drugmakers could capture $3-5 billion of the opportunity, while GSK and Bristol Myers Squibb prepare for revenue losses.
Major biotech investment and M&A activity marked early 2026, including a significant stake purchase in TG Therapeutics and multiple high-value acquisitions within the RTW Biotech Opportunities portfolio. The sector showed improving capital markets and strategic deal interest following the JPMorgan Healthcare Conference.
The UK and US announced a pharmaceuticals agreement featuring zero tariffs and a 25% increase in UK spending on innovative medicines. Major pharma M&A deals and regulatory reforms are reshaping the industry in early 2026.
